Tech-enabled urgent care provider Remedy this morning announced a $10 million Series A funding round led by Santé Ventures, an Austin, Texas-based firm with a focus on healthcare and the life sciences. 

As part of the deal, Dr. Joe Cunningham and Doug French, both managing directors at Santé Ventures, will be taking seats on Remedy’s board. 

WHAT THEY DO

Remedy provides both video conferencing with clinicians and house calls through an app. The service is able to treat common aliments like the cold, flu, pink eye, rashes and bronchitis. Patients are also able to get their prescription refills for medications such as birth control, antidepressants and cholesteral medications through the platform. Lastly, the company is able to run lab tests for certain infections like sexually transmitted disease, yeast infections and urinary track infections.

Remedy has provider partners, which are made up of doctors, physicians’ assistants and advanced practice nurses, according to its webpage. The startup notes that its providers are in-network for Aetna, Blue Cross, Cigna, Humana and United Healthcare. 

WHAT IT'S FOR 

The new money will go toward scaling Remedy's technology and expanding its offerings for self-funded employers.

"After reviewing numerous telemedicine companies in recent years, we feel confident Remedy can scale beyond traditional primary care delivery and is well-positioned to dramatically lower costs and improve outcomes for high-cost procedures and chronic disease management," Cunningham said. "The market potential for coordinated care delivery and chronic disease management from a telemedicine platform is the next evolution of this technology."

MARKET SNAPSHOT

This combination of tech-enabled house calls and video conferences is not Remedy's alone. In May, Heal, maker of an app for booking and processing physician house calls, announced its plans to create a built-in telemedicine feature that customers may use to conduct voice or video calls with a provider. Others like Dispatch Health are focusing their tech-driven service solely on the house call component. 

ON THE RECORD

"After reviewing numerous telemedicine companies in recent years, we feel confident Remedy can scale beyond traditional primary care delivery and is well-positioned to dramatically lower costs and improve outcomes for high-cost procedures and chronic disease management," Cunningham said in a statement. "The market potential for coordinated care delivery and chronic disease management from a telemedicine platform is the next evolution of this technology."